Fresh off its bid to become a public company, Novocure Ltd. (St. Helier, Jersey Isle) received FDA approval for its Optune device in combination with temozolomide to treat adult patients with newly diagnosed glioblastoma (GBM). Optune is a portable, non-invasive device that delivers low-intensity, intermediate frequency, alternating electric fields – referred to as tumor treating fields (TTF) – that inhibit cancer cell replication and cause cancer cell death. Read More
